The End of Dual Therapy with Renin–Angiotensin–Aldosterone System Blockade?
Author:
- 14 November 2013
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 369 (20) , 1960-1962
Abstract
Treatment aimed at multiple risk factors and specific markers such as glucose level, blood pressure, body weight, cholesterol levels, and albuminuria has been the main focus to slow cardiovascular and renal risk among patients with diabetes. Among the agents used, those that interrupt the renin–angiotensin–aldosterone system (RAAS) have shown protection that extends beyond decreasing blood pressure. In part, these additional effects may be explained by a decrease in albuminuria.1 Therefore, angiotensin-converting–enzyme (ACE) inhibitors and angiotensin II–receptor blockers (ARBs) have become first-choice drugs in patients with diabetes. Despite some success, the residual cardiovascular and renal risk among patients with diabetes remains . . .Keywords
This publication has 9 references indexed in Scilit:
- Combined Angiotensin Inhibition for the Treatment of Diabetic NephropathyNew England Journal of Medicine, 2013
- Novel drugs and intervention strategies for the treatment of chronic kidney diseaseBritish Journal of Clinical Pharmacology, 2013
- Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trialsBMJ, 2013
- Efficacy and Safety of Combined vs. Single Renin-Angiotensin-Aldosterone System Blockade in Chronic Kidney Disease: A Meta-AnalysisAmerican Journal of Hypertension, 2013
- Cardiorenal End Points in a Trial of Aliskiren for Type 2 DiabetesNew England Journal of Medicine, 2012
- Unmet Need in Renal Protection – Do We Need a More Comprehensive Approach?2011
- Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trialDiabetologia, 2010
- Rosiglitazone RevisitedArchives of internal medicine (1960), 2010
- Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular EventsNew England Journal of Medicine, 2008